Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result
- PMID: 17980284
- DOI: 10.1016/j.jvs.2007.06.046
Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result
Abstract
Background: Stenting of chronic nonmalignant obstruction in the venous outflow tract started in earnest in 1997. Data sets are now available to perform long-term analysis of stent-related outcome and clinical and hemodynamic results of this intervention.
Materials: From 1997 to 2005, 982 chronic nonmalignant obstructive lesions of the femoroiliocaval vein were stented under intravascular ultrasound guidance. Median patient age was 54 years (range, 14 to 90 years), the female/male was 2.6:1, and left/right limb symptoms, 2.4:1. Clinical score of CEAP was 2 in 7%, 3 in 47%, 4 in 24%, 5 in 5%, and 6 in 17%; primary/secondary etiology was 518:464. Stent-related outcome (morbidity, thrombotic events, patency, in-stent recurrent stenosis), clinical outcome, quality of life (QOL) as assessed by the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), and hemodynamics were evaluated before and after intervention.
Result: Monitoring for 94% of patients lasted a mean 22 months (range, 1 to 107 months). Stenting was performed with no mortality (<30 days) and low morbidity. Thrombotic events were rare (1.5%) during the postoperative period (<30 days) and during later follow-up (3%). At 72 months, primary, assisted-primary, and secondary cumulative patency rates were 79%, 100%, and 100% in nonthrombotic disease and 57%, 80%, and 86% in thrombotic disease, respectively. Cumulative rate of severe in-stent restenosis (>50%) occurred in 5% of limbs at 72 months (10% in thrombotic limbs, 1% in nonthrombotic limbs). The main risk factors associated with stent occlusion were the presence and severity of thrombotic disease; thrombophilia by itself was not a risk factor. The median pain score and degree of swelling decreased significantly poststent. Severe leg pain (visual analogue scale >5) and leg swelling (grade 3) decreased from 54% and 44% prestent to 11% and 18% poststent, respectively. At 5 years, cumulative rates of complete relief of pain and swelling were 62% and 32%, respectively, and ulcer healing was 58%. The mean CIVIQ scores of QOL improved significantly in all categories. Mean hand-foot pressure differential decreased and mean ambulatory venous pressure improved in stented limbs with no concomitant reflux. The hemodynamic response was modified, depending on the presence of deep and superficial reflux in subsets of patients with adjunct saphenous procedures. No increase in venous reflux was observed.
Conclusions: Venous stenting can be performed with low morbidity and mortality, long-term high patency rate, and a low rate of in-stent restenosis. It resulted in major symptom relief in patients with chronic venous disease, which was not consistently reflected in any substantial hemodynamic improvement by conventional measurements. The beneficial clinical outcome occurred regardless of presence of remaining reflux, adjunct saphenous procedures, or etiology of obstruction.
Similar articles
-
Unexpected major role for venous stenting in deep reflux disease.J Vasc Surg. 2010 Feb;51(2):401-8; discussion 408. doi: 10.1016/j.jvs.2009.08.032. Epub 2009 Dec 14. J Vasc Surg. 2010. PMID: 20006920
-
Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease.J Vasc Surg. 2006 Oct;44(4):828-33. doi: 10.1016/j.jvs.2006.06.026. J Vasc Surg. 2006. PMID: 17012006
-
The clinical impact of iliac venous stents in the management of chronic venous insufficiency.J Vasc Surg. 2002 Jan;35(1):8-15. doi: 10.1067/mva.2002.121054. J Vasc Surg. 2002. PMID: 11802127
-
Treatment of iliac-caval outflow obstruction.Semin Vasc Surg. 2015 Mar;28(1):47-53. doi: 10.1053/j.semvascsurg.2015.07.001. Epub 2015 Jul 17. Semin Vasc Surg. 2015. PMID: 26358309 Review.
-
Comparison between a dedicated venous stent and standard composite Wallstent-Z stent approach to iliofemoral venous stenting: Intermediate-term outcomes.J Vasc Surg Venous Lymphat Disord. 2023 Jan;11(1):82-90.e2. doi: 10.1016/j.jvsv.2022.05.012. Epub 2022 Jul 21. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 35872144 Review.
Cited by
-
Early Thrombus Removal for Acute Lower Extremity Deep Vein Thrombosis: Update on Inclusion, Technical Aspects, and Postprocedural Management.Cardiovasc Intervent Radiol. 2024 Nov 14. doi: 10.1007/s00270-024-03898-4. Online ahead of print. Cardiovasc Intervent Radiol. 2024. PMID: 39542879 Review.
-
DETECT-DVT: Detroit Evaluation of Thrombectomy and Evaluation of Intravascular Ultrasound in Deep Vein Thrombosis.J Soc Cardiovasc Angiogr Interv. 2024 Sep 20;3(10):102153. doi: 10.1016/j.jscai.2024.102153. eCollection 2024 Oct. J Soc Cardiovasc Angiogr Interv. 2024. PMID: 39525990 Free PMC article.
-
Management of Iliofemoral Venous Stent Thrombosis.Semin Intervent Radiol. 2024 Nov 7;41(4):424-429. doi: 10.1055/s-0044-1791191. eCollection 2024 Aug. Semin Intervent Radiol. 2024. PMID: 39524234 Review. No abstract available.
-
Safety and efficacy assessment of the Inno-Xmart venous stent system in managing symptomatic iliofemoral venous obstruction: a 12-month outcome analysis.Cardiovasc Interv Ther. 2024 Oct 4. doi: 10.1007/s12928-024-01037-x. Online ahead of print. Cardiovasc Interv Ther. 2024. PMID: 39365550
-
Analysis of computed tomography venography for the diagnosis and endovascular treatment of iliac venous compression syndrome with venous leg ulcers: a retrospective study.Sci Rep. 2024 Sep 27;14(1):22314. doi: 10.1038/s41598-024-72425-9. Sci Rep. 2024. PMID: 39333192 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
